Bone densitometry firm Hologic will showcase the expansion ofits QDR-4500 Acclaim line of dual-energy x-ray absorptiometryscanners, which debuted at last year's RSNA meeting with the introductionof the QDR-4500A system. Hologic, of Waltham, MA, has added
Bone densitometry firm Hologic will showcase the expansion ofits QDR-4500 Acclaim line of dual-energy x-ray absorptiometryscanners, which debuted at last year's RSNA meeting with the introductionof the QDR-4500A system.
Hologic, of Waltham, MA, has added three new DEXA scanners tothe line, to be positioned at price points below the flagshipQDR-4500A. QDR-4500C is for spine and hip scanning, QDR-4500Wis targeted at spine, hip and total body work, and QDR-4500SLis for spine, hip and lateral scanning, according to Joel Weinstein,vice president of business development and marketing. Any of thenew scanners can be upgraded to the QDR-4500A.
Hologic will also show a new ultrasound bone densitometry productcalled Sahara. Sahara is based on technology Hologic acquiredwhen it bought WalkerSonix earlier this year. Sahara differs fromthe WalkerSonix devices and other ultrasound densitometers onthe market in that it does not require a water bath for bone scanning,Weinstein said.
Hologic this month reported strong financial results for its1995 fiscal year due to increased interest in bone densitometry.The company saw revenues increase 13% to $43.4 million while netincome stood at $1.9 million, a drop of 38% caused by legal costsassociated with its patent litigation with Lunar. The financialresults prompted the company's stock to surge 13% on Nov. 8 to$29.75 a share.
New Literature Review Assesses Merits of Cardiac MRI After Survival of Sudden Cardiac Arrest
April 19th 2024While noting inconsistencies with the diagnostic yield of cardiac MRI in patients who survived sudden cardiac arrest, researchers cited unique advantages in characterizing ischemic cardiomyopathy (ICM) and facilitating alternate diagnoses.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.